GlobeNewswire: Endonovo Therapeutics, Inc. Contains the last 10 of 117 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:20:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854076/0/en/Endonovo-Closes-Asset-Purchase-Agreement-for-a-Minimum-of-50M-With-SofPulse-Inc.html?f=22&fvtc=4&fvtv=43541Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc2024-03-28T13:03:00Z<![CDATA[Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million.]]>https://www.globenewswire.com/news-release/2024/03/04/2839681/0/en/Endonovo-s-SofPulse-to-Be-Featured-at-Innovative-Pain-Management-Solutions.html?f=22&fvtc=4&fvtv=43541Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions2024-03-04T14:09:00Z<![CDATA[US Army Medical Research and Development Command Vendor Day]]>https://www.globenewswire.com/news-release/2023/12/04/2790115/0/en/Endonovo-Signs-Definitive-Agreement-to-Sell-SofPulse-Brand-Business-and-IP-to-SofPulse-Inc-for-a-minimum-of-50-Million.html?f=22&fvtc=4&fvtv=43541Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million2023-12-04T14:15:00Z<![CDATA[Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's asset valuation acceptable to the Endonovo board. It was further agreed, that SofPulse, Inc. will prepare to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.]]>https://www.globenewswire.com/news-release/2023/10/12/2759320/0/en/Endonovo-s-SofPulse-Secures-Taiwan-FDA-Approval.html?f=22&fvtc=4&fvtv=43541Endonovo's SofPulse® Secures Taiwan FDA Approval2023-10-12T13:07:00Z<![CDATA[Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW).]]>https://www.globenewswire.com/news-release/2023/08/22/2729608/0/en/Endonovo-s-SofPulse-Secures-Federal-Supply-Schedule-Inclusion-to-Accelerate-Expansion-of-VA-Distribution.html?f=22&fvtc=4&fvtv=43541Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution2023-08-22T13:07:00Z<![CDATA[Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse® Pulsed Electro Magnetic Field (PEMF) medical devices for distribution throughout the Federal healthcare supply channels.]]>https://www.globenewswire.com/news-release/2023/08/08/2720759/0/en/Endonovo-s-Breaking-Barriers-in-With-Patented-Medical-Technologies-2023-Bi-Annual-Update.html?f=22&fvtc=4&fvtv=43541Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update2023-08-08T13:03:00Z<![CDATA[Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first half of 2023.]]>https://www.globenewswire.com/news-release/2023/06/07/2683840/0/en/Endonovo-Pending-Agreement-to-Develop-Telehealth-Division.html?f=22&fvtc=4&fvtv=43541Endonovo Pending Agreement to Develop Telehealth Division2023-06-07T13:07:00Z<![CDATA[Los Angeles, CA, June 07, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), an industry leading medical technology company, is working with a prominent developer of telehealth (telemedicine) platforms to establish a new telehealth division for Endonovo.]]>https://www.globenewswire.com/news-release/2023/05/02/2659301/0/en/Endonovo-Launches-SofPulse-into-the-Veterans-Administration.html?f=22&fvtc=4&fvtv=43541Endonovo Launches SofPulse® into the Veterans Administration2023-05-02T13:03:00Z<![CDATA[Los Angeles, CA, May 02, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) a US-based biotechnology developer, today announced the launch of SofPulse® with Academy Medical, Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller.]]>https://www.globenewswire.com/news-release/2023/04/25/2654014/0/en/Endonovo-Reaches-Out-to-Top-Clinical-Researchers-to-Collaborate-on-TBI-Treatment-Studies.html?f=22&fvtc=4&fvtv=43541Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies2023-04-25T13:07:00Z<![CDATA[Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment.]]>https://www.globenewswire.com/news-release/2023/04/13/2646305/0/en/Endonovo-Announces-Partnership-with-Former-NFL-Dallas-Cowboy-Defensive-Lineman.html?f=22&fvtc=4&fvtv=43541Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman2023-04-13T13:07:00Z<![CDATA[Los Angeles, CA, April 13, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership with David Irving, former NFL (National Football League) defensive lineman, as brand ambassador for SofPulse®, a non-opioid pain and inflammation relief technology.]]>